These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Wacker DA; Miller KJ Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561 [TBL] [Abstract][Full Text] [Related]
4. Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Ahmad S; Ngu K; Miller KJ; Wu G; Hung CP; Malmstrom S; Zhang G; O'Tanyi E; Keim WJ; Cullen MJ; Rohrbach KW; Thomas M; Ung T; Qu Q; Gan J; Narayanan R; Pelleymounter MA; Robl JA Bioorg Med Chem Lett; 2010 Feb; 20(3):1128-33. PubMed ID: 20022752 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Liu KK; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons C; Maurer TS; Marala R; Brown J; Kong JX; Lee E; Werner W; Wenzel Z; Vage C Bioorg Med Chem Lett; 2010 Jan; 20(1):266-71. PubMed ID: 19914063 [TBL] [Abstract][Full Text] [Related]
6. Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity. Liu KK; Lefker BA; Dombroski MA; Chiang P; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons CP; Marala R; Brown JA; Kong JX; Lee E; Werner W; Wenzel Z; Giragossian C; Chen H; Coffey SB Bioorg Med Chem Lett; 2010 Apr; 20(7):2365-9. PubMed ID: 20202843 [TBL] [Abstract][Full Text] [Related]
7. Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Hayashi A; Sonoda R; Kimura Y; Takasu T; Suzuki M; Sasamata M; Miyata K Brain Res; 2004 Jun; 1011(2):221-7. PubMed ID: 15157808 [TBL] [Abstract][Full Text] [Related]
14. Approaches to antiobesity therapy. An introduction. Bishop MJ J Med Chem; 2006 Jul; 49(14):3999-4000. PubMed ID: 16821758 [No Abstract] [Full Text] [Related]
15. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? Miller KJ; Wacker DA Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799 [TBL] [Abstract][Full Text] [Related]
16. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Miller KJ Mol Interv; 2005 Oct; 5(5):282-91. PubMed ID: 16249524 [TBL] [Abstract][Full Text] [Related]
17. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807 [TBL] [Abstract][Full Text] [Related]